Bet on JNJ & Hold on to Apple to Grow Your Retirement Fund Stress-FreeZacks Investment Research • 08/08/25
J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?Zacks Investment Research • 08/04/25
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8.5% (August 2025)Seeking Alpha • 08/02/25
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challengesWSJ • 08/01/25
Johnson & Johnson to Participate in the Morgan Stanley 23rd Annual Global Healthcare ConferenceBusiness Wire • 07/30/25
Boston Jury Hits Johnson & Johnson with Record $42M Verdict in Asbestos Baby Powder CaseBusiness Wire • 07/29/25
Dow Jones Health Care Giant J&J, Three Others In Or Near Buy ZonesInvestors Business Daily • 07/29/25
Johnson & Johnson Launches VIRTUGUIDE™ AI-Powered Patient-Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for MillionsPRNewsWire • 07/29/25
Johnson & Johnson files with U.S. FDA to include new evidence in TREMFYA® (guselkumab) label as the only IL-23 inhibitor to demonstrate significant inhibition of joint structural damage in active psoriatic arthritisPRNewsWire • 07/29/25
4 High-Yield Blue-Chip Pharmaceutical Giants Offer Huge Total Return Potential24/7 Wall Street • 07/28/25